合成人ABCB4 mRNA疗法可挽救PFIC3小鼠模型的严重肝病表型
PFIC3由ABCB4基因功能缺失变异引起,目前除肝移植外无有效治疗。研究制备经化学和遗传修饰的人ABCB4 mRNA并封装于脂质纳米颗粒,在细胞模型及BALB/c.Abcb4-/-小鼠模型中验证其药理作用,结果显示重复注射可快速显著逆转炎症、胆管反应和肝纤维化等临床相关指标。
要点
- 肝靶向hABCB4 mRNA可在细胞和PFIC3小鼠肝脏中重新表达功能性hABCB4蛋白并恢复磷脂转运。
- 重复注射hABCB4 mRNA可有效挽救年轻Abcb4-/-小鼠的严重疾病表型。
- 该疗法促进肝细胞驱动的肝再生,恢复肝重、体重、肝酶和门静脉血压等正常稳态。
核心结论
- 研究数据为hABCB4 mRNA疗法作为PFIC3患者潜在治疗选择提供了强有力的临床前概念验证。
研究设计与样本
- 研究制备并筛选了封装于脂质纳米颗粒的经化学和遗传修饰的人ABCB4 mRNA变体。
- 在细胞模型和因Abcb4基因纯合破坏而类似人类PFIC3的纤维化易感BALB/c.Abcb4-/-小鼠模型中检验药理效应。
主要发现
- 肝靶向hABCB4 mRNA治疗导致功能性hABCB4蛋白的从头表达,并在培养细胞和PFIC3小鼠肝脏中恢复磷脂转运。
- 重复注射hABCB4 mRNA有效挽救年轻Abcb4-/-小鼠的严重疾病表型,炎症、胆管反应和肝纤维化等所有临床相关参数快速且显著正常化。
- 合成mRNA疗法促进有利的肝细胞驱动肝再生,恢复肝重、体重、肝酶和门静脉血压等正常稳态。
临床怎么用
- 该临床前结果为PFIC3患者提供了除肝移植外的一种潜在mRNA治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Progressive familial intrahepatic cholestasis type 3 (PFIC3) is a rare lethal autosomal recessive liver disorder caused by loss-of-function variations of the ABCB4 gene, encoding a phosphatidylcholine transporter (ABCB4/MDR3). Currently, no effective treatment exists for PFIC3 outside of liver transplantation. METHODS: We have produced and screened chemically and genetically modified mRNA variants encoding human ABCB4 (hABCB4 mRNA) encapsulated in lipid nanoparticles (LNPs). We examined their pharmacological effects in a cell-based model and in a new in vivo mouse model resembling human PFIC3 as a result of homozygous disruption of the Abcb4 gene in fibrosis-susceptible BALB/c.Abcb4-/- mice. RESULTS: We show that treatment with liver-targeted hABCB4 mRNA resulted in de novo expression of functional hABCB4 protein and restored phospholipid transport in cultured cells and in PFIC3 mouse livers. Importantly, repeated injections of the hABCB4 mRNA effectively rescued the severe disease phenotype in young Abcb4-/- mice, with rapid and dramatic normalisation of all clinically relevant parameters such as inflammation, ductular reaction, and liver fibrosis. Synthetic mRNA therapy also promoted favourable hepatocyte-driven liver regeneration to restore normal homeostasis, including liver weight, body weight, liver enzymes, and portal vein blood pressure. CONCLUSIONS: Our data provide strong preclinical proof-of-concept for hABCB4 mRNA therapy as a potential treatment option for patients with PFIC3. LAY SUMMARY: This report describes the development of an innovative mRNA therapy as a potential treatment for PFIC3, a devastating rare paediatric liver disease with no treatment options except liver transplantation. We show that administration of our mRNA construct completely rescues severe liver disease in a genetic model of PFIC3 in mice.
引用
- Wei G, Cao J, Huang P, et al. Synthetic human ABCB4 mRNA therapy rescues severe liver disease phenotype in a BALB/c.Abcb4-/- mouse model of PFIC3. J Hepatol. 2020. PMID: 33340584. doi:10.1016/j.jhep.2020.12.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。